Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Immunocore Holdings plc reported revenue of $400M, up 29.0% year over year. Operating margin was -11.3% and net margin -8.9%, on a free-cash-flow margin of -3.8% with capital expenditure at 1.1% of revenue. Every figure is computed directly from IMCR's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $400M | -11.3% | -8.9% |
| FY2024 | $310M | -22.7% | -16.5% |
| FY2023 | $249M | -23.9% | -22.2% |
| FY2022 | $174M | -29.7% | -30.1% |
| FY2021 | $36M | -478.5% | -493.4% |
How does IMCR compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.